ipilimumab
bms
['yervoy', 'melanoma']
first phase 3 trial of til cell therapy for a solid tumour shows 50% improvement on ctla4 inhibitor yervoy in advanced #melanoma unresponsive to pd-1 inhibitor therapy at #esmo22 
https://t.co/O0ZJQGuINh, and its digital magazine Deep Dive, is a leading online destination for healthcare and pharmaceutical industry news, insight and debate